Reviewing Books: Tapestry by Laurel Lee
With summer fading, I am getting to a number of lymphoma book reviews I have not had time to do.
Tapestry is the biography of Laurel Lee, who was diagnosed with Hodgkin's in 1975 at age 29. The first part of her journey is chronicled in the book Walking Through the Fire later made into a CBS television movie. Tapestry starts in the 1960's with Laurel hitchhiking to Alaska and winds its way through the 70's, 80's, and 90's with humor and grace. The story is bittersweet - although she survived her lymphoma, her story comes to a conclusion when she was diagnosed with late stage Pancreatic cancer, surviving ten months when given three. Her accounts leave the reader with warmth and understanding. An accomplished writer, Laurel's account is a good read and recommended.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
